Navigation Links
Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada
Date:6/6/2008

TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.

Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.

In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.

"The real value of Oxyzyme is that it combines two agents - iodine and oxygen - that are essential to the process of wound healing and provides further opportunities to overcome barriers to healing that may exist in the patient," explained Dr. Keith Harding, leading figure in the international wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.

About Insense Ltd.

------------------ Insense is a British biotechnology company founded by Professor Paul Davis, Chief Scientific Officer, who led the team which invented and developed the ClearBlue(TM) pregnancy test. The company is also developing products out of its core technology for dermatology and health and beauty applications. For more information about Insense Ltd. visit http://www.insense.co.uk.


'/>"/>
SOURCE Insense Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ORF Genetics Opens Revolutionary Green Factory in Iceland
2. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
3. SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
4. NASA MidSTAR-1 successful technologies may be revolutionary
5. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
6. Webcam MD - Launch of revolutionary web-based medical technology
7. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
8. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
9. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Rhythm, ... rare genetic deficiencies that result in life-threatening ... a $41 million mezzanine round of financing ... OrbiMed, MPM Capital, New Enterprise Associates, Pfizer ... undisclosed public healthcare investment fund. Rhythm will ...
(Date:2/15/2017)... Clara, CA (PRWEB) , ... February 15, 2017 , ... ... announced that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with ... SmartScan completely automatizes all of the functions of setting up and taking the image ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ ... ), a biotechnology company focused on developing aerosolized ... that it has completed a $10.5 million private ... expects that it has sufficient capital to fund ... 2b clinical trial data release in mid-2017. ...
(Date:2/15/2017)... , Feb. 15, 2017  Surrozen Inc., a ... drugs that promote the repair and regeneration of human ... led by The Column Group, a science-driven venture capital ... The funds will be used to implement a broad-based ... of Wnt signaling, which plays a central role in ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 7, 2017 ... Driven largely by the confluence of organizations, desires ... distaste for knowledge-based systems (password and challenge questions), ... industrial, and government systems. The market is driven ... a demarcation between consumer and enterprise uses cases, ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):